The FDA has approved RediTrex (methotrexate injection; Cumberland) for the management of patients with severe, active rheumatoid arthritis (RA) and polyarticular juvenile idiopathic arthritis, who are intolerant of or had an inadequate response to first-line therapy.
Treatment with biologics for psoriasis is not the same for men and women, a study shows, and may explain why women tend toward earlier discontinuation with biologic treatment.
In this study, patients with psoriasis appeared to have an increased risk for cancer incidence and cancer-related mortality involving a range of site-specific cancers.
Pustular psoriasis linked to arthritis onset two years earlier; increased delay seen for plaque psoriasis
Researchers compared the association of potential risk factors for the development of psoriasis, psoriatic arthritis, rheumatoid arthritis, and ankylosing spondylitis.
Researchers assessed the effect of uveitis, psoriasis, and inflammatory bowel disease on disease activity and functional status in a population-based cohort of patients with axial spondyloarthritis.
Bimekizumab (UCB), an investigational treatment for moderate-to-severe plaque psoriasis, met its two primary end points in a second phase 3 trial.
Researchers reported on the efficacy of secukinumab in patients with psoriatic arthritis and nail psoriasis and other elements of the disease, including radiographic progression.
No differences in the risk for major cardiovascular events were found between etanercept, adalimumab, and ustekinumab in adult patients with moderate to severe plaque psoriasis following short- to medium-term exposure.
The potential of the evaluated technology is that it allows for objective evaluation and should therefore, the researchers believe, be developed as an alternative method to human assessment.
